- Conditions
- Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Cancer AJCC v7, Stage IIA Esophageal Cancer AJCC v7, Stage IIB Esophageal Cancer AJCC v7, Stage IIIA Esophageal Cancer AJCC v7, Stage IIIB Esophageal Cancer AJCC v7
- Interventions
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment, Radiation Therapy, Therapeutic Conventional Surgery, Trastuzumab
- Drug · Other · Radiation + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2023
- U.S. locations
- 634
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 407 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 28
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Acute Lymphoblastic Leukemia, Childhood Acute Lymphoblastic Leukemia
- Interventions
- Biospecimen Collection, Compliance Monitoring, Health Promotion and Education, Informational Intervention, Media Intervention, Medical Device Usage and Evaluation, Mercaptopurine, Questionnaire Administration, Telephone-Based Intervention, Training and Education
- Procedure · Behavioral · Other + 1 more
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 27
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Oakland, California + 20 more
- Conditions
- Muscle-Invasive Bladder Carcinoma, Gastroesophageal Adenocarcinoma, Melanoma, Non-small Cell Lung Cancer
- Interventions
- Synthetic long peptide personalized cancer vaccine, Poly ICLC, Signatera assay
- Biological · Drug · Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2034
- U.S. locations
- 3
- States / cities
- Orlando, Florida • St Louis, Missouri • Columbus, Ohio
- Conditions
- Colorectal Cancer
- Interventions
- fluorouracil, leucovorin calcium, levamisole hydrochloride, radiation therapy
- Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 1,917 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2008
- U.S. locations
- 35
- States / cities
- Scottsdale, Arizona • Denver, Colorado • Tampa, Florida + 29 more
- Conditions
- Breast Carcinoma
- Interventions
- quality-of-life assessment, Questionnaire Administration
- Other
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 307 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 227
- States / cities
- Mobile, Alabama • Fort Smith, Arkansas • Fresno, California + 154 more
- Conditions
- Melanoma
- Interventions
- pBCAR3-phosphopeptide, pIRS2-phosphopeptide, 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)
- Biological
- Lead sponsor
- Craig L Slingluff, Jr
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma
- Interventions
- Carboplatin, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Selumetinib Sulfate, Vincristine Sulfate
- Drug · Procedure · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 125
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 101 more
- Conditions
- Melanoma
- Interventions
- MELITAC 12.1, Imiquimod
- Biological · Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Campylobacter Infection
- Interventions
- ALFQ, CJCV2
- Drug · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Erythroid Leukemia (M6), Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia (M5), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
- Interventions
- cytarabine, daunorubicin hydrochloride, etoposide, valspodar, filgrastim, busulfan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, aldesleukin, clinical observation, pharmacological study
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 15 Years to 59 Years
- Enrollment
- 720 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2000
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Lymphoblastic Lymphoma, Ann Arbor Stage I B Lymphoblastic Lymphoma, Ann Arbor Stage II B Lymphoblastic Lymphoma, Childhood B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Childhood B Lymphoblastic Lymphoma, Down Syndrome, Hypodiploid B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Positive
- Interventions
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Leucovorin Calcium, Mercaptopurine, Methotrexate, Pegaspargase, Quality-of-Life Assessment, Questionnaire Administration, Thioguanine, Vincristine Sulfate
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 9,350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 213
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 153 more
- Conditions
- Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
- Interventions
- mFOLFIRINOX, Algenpantucel-L Immunotherapy, SBRT, Gemcitabine
- Drug · Biological · Radiation
- Lead sponsor
- NewLink Genetics Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Louisville, Kentucky • Burlington, Massachusetts • Albuquerque, New Mexico + 1 more
- Conditions
- Prostate Cancer
- Interventions
- recombinant viral vaccine therapy, sargramostim
- Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1996
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Cutaneous Lupus, Lupus
- Interventions
- AMG 557, AMG 557 Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 7
- States / cities
- Birmingham, Alabama • Ann Arbor, Michigan • Philadelphia, Pennsylvania + 2 more
- Conditions
- Healthy
- Interventions
- Placebo, RSV preF Protein 50 mcg, RSV preF Protein 150 mcg, Ad26.RSV.preF 1*10^11 vp, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 5*10^10 vp Plus RSV preF Protein 150 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 50 mcg, Mixture of Ad26.RSV.preF 1*10^11 vp Plus RSV preF Protein 150 mcg, Selected Regimen
- Biological
- Lead sponsor
- Janssen Vaccines & Prevention B.V.
- Industry
- Eligibility
- 60 Years and older
- Enrollment
- 669 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 6
- States / cities
- Huntsville, Alabama • San Diego, California • Melbourne, Florida + 3 more
- Conditions
- Neuroblastoma
- Interventions
- Radiation: 131I-MIBG, Dinutuximab, Vorinostat
- Drug
- Lead sponsor
- New Approaches to Neuroblastoma Therapy Consortium
- Other
- Eligibility
- 1 Year to 30 Years
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 13
- States / cities
- Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
- Conditions
- Prostate Cancer
- Interventions
- white button mushroom extract, flow cytometry, immunologic technique, laboratory biomarker analysis, gas chromatography-mass spectrometry, pharmacological study
- Drug · Other
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- Male only
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2021
- U.S. locations
- 2
- States / cities
- Duarte, California • South Pasadena, California
- Conditions
- Advanced Cancers, Solid Tumors
- Interventions
- Panax Ginseng, Placebo, Questionnaires
- Drug · Dietary Supplement · Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 165 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2028
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Macular Degeneration
- Interventions
- BI 754132
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 8
- States / cities
- Beverly Hills, California • Pensacola, Florida • Winter Haven, Florida + 5 more
- Conditions
- Adverse Childhood Experiences
- Interventions
- Moderate Intensity Exercise (one day), Placebo - Light Intensity Exercise (one day), Moderate Intensity Exercise (9 wks), Day 1 Assessments, Symptom Measures and Neuropsychological Tests, Day 36 Assessments, Day 57 Assessments, Day 78 Assessments
- Behavioral · Other
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 40 Years to 60 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Normal Female Volunteers
- Interventions
- HP802-247
- Biological
- Lead sponsor
- Healthpoint
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Irving, Texas
- Conditions
- Kidney Transplantation
- Interventions
- Belatacept, Tacrolimus, Cyclosporine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 446 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 60
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 46 more
- Conditions
- Keratosis, Actinic
- Interventions
- Tirbanibulin ointment 1%
- Drug
- Lead sponsor
- Almirall, S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022
- U.S. locations
- 7
- States / cities
- Hot Springs, Arkansas • Encinitas, California • Sweetwater, Florida + 4 more
- Conditions
- Leukemia
- Interventions
- filgrastim, cyclophosphamide, cytarabine, daunorubicin, dexamethasone, doxorubicin, leucovorin, mercaptopurine, methotrexate, mitoxantrone, Asparaginase, prednisone, thioguanine, vincristine, radiation therapy, allopurinol, bactrim
- Biological · Drug · Radiation
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 78
- States / cities
- Burbank, California • Maywood, Illinois • Chanute, Kansas + 45 more